GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4)
GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4)
MENLO PARK, Calif., Aug. 30, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 182,223 shares of GRAIL's common stock to 55 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).
2024年8月30日，加利福尼亞門洛帕克——GRAIL股份有限公司（納斯達克股票代碼：GRAL），一家專注於早期癌症檢測的醫療保健公司，宣佈已授予182,223股GRAIL普通股的限制性股票單元（RSUs）激勵55名最近受聘非高管員工，以吸引他們接受GRAIL的聘用。這些聘用激勵獎項根據GRAIL的聘用激勵股權激勵計劃和相關的限制性股票授予協議根據納斯達克相關規定第5635(c)(4)條款授予。
The inducement plan is used exclusively for the grant of equity awards to individuals who were not previously employees of GRAIL, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with GRAIL, pursuant to Nasdaq Listing Rule 5635(c)(4).
激勵計劃僅用於授予GRAIL以前未曾任職的個人股權獎勵，或者在真實休職期結束後，作爲激勵條件，吸引這些人與GRAIL簽訂勞動合同，根據納斯達克相關規定第5635(c)(4)條款。
The RSUs vest over an approximately four year period, with 25% of the award vesting in either May or August, 2025, depending on the start date of the employee, and on each one year anniversary of those respective dates thereafter, subject to continued employment with GRAIL (or any successor to or subsidiary of the Company) through the vesting dates.
這些限制性股票單元（RSUs）將在約四年的時間內解鎖，分爲2025年5月或8月的25%解鎖，並在此後的每個紀念日再解鎖一部分，具體解鎖日期取決於員工的入職日期，並以繼續在GRAIL（或任何該公司的繼任者或子公司）任職爲前提。
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. GRAIL's targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. GRAIL is headquartered in Menlo Park, CA with locations in Washington, D.C., North Carolina, and the United Kingdom.
關於GRAIL
GRAIL是一家醫療保健公司，其使命是利用下一代測序、大規模人群臨床研究以及最先進的機器學習、軟件和自動化技術，檢測和鑑定早期多種致命癌症類型，以緩解全球癌症負擔。GRAIL的靶向甲基化平台可支持篩查和精準腫瘤學的醫療連續體，包括症狀患者的多癌症早期檢測、風險分層、最小殘留病檢測、生物標誌物亞型分型、治療和復發監測。GRAIL總部位於加利福尼亞州門洛帕克，設在華盛頓特區、北卡羅來納州和英國。
For more information, visit grail.com.
要獲取更多信息，請訪問grail.com.
SOURCE GRAIL, Inc.
出處：GRAIL，Inc.
譯文內容由第三人軟體翻譯。